Cempra (CEMP) Shares are Down -3.91%

Cempra (CEMP) has risen sharply, recording gains of 25.17% in the past 4 weeks. However, the stock has corrected -3.91% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 24.69% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

Cempra, Inc. is up 43.59% in the last 3-month period. Year-to-Date the stock performance stands at -27.3%. The stock has recorded a 20-day Moving Average of 5.9% and the 50-Day Moving Average is 17.22%.


Cempra (NASDAQ:CEMP): The stock opened at $23.28 on Friday but the bulls could not build on the opening and the stock topped out at $23.59 for the day. The stock traded down to $22.50 during the day, due to lack of any buying support eventually closed down at $22.63 with a loss of -3.46% for the day. The stock had closed at $23.44 on the previous day. The total traded volume was 838,332 shares.

Also, Equity Analysts at the Brokerage Firm, Jefferies, maintains their rating on the shares of Cempra (NASDAQ:CEMP). Jefferies has a Buy rating on the shares. As per the latest research report, the brokerage house lowers the price target to $40 per share from a prior target of $42. The rating by the firm was issued on August 2, 2016.

Cempra Inc. is a clinical-stage pharmaceutical company focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Companys lead product, solithromycin, is being developed in oral capsules, intravenous, or IV, and suspension formulations, initially for the treatment of community acquired bacterial pneumonia, or CABP, an infection of the respiratory tract. The Companys second product is Taksta, an antibiotic known as fusidic acid, that has been used for decades outside the United States, including Western Europe, but , which has never been approved in the United States. The Company is developing Taksta in the United States as an oral treatment of refractory bone and joint infections caused by staphylococci.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *